secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirum Pharmaceuticals, Inc. (MIRM)
CIK:        0001759425
Form:       8-K
Filed at:   2023-09-11T23:59:59+00:00
Accession:  0001193125-23-232481
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirum appoints Eric Bjerkholt as CFO effective Sept 11, 2023
------------------------------------------------------------

- Eric Bjerkholt appointed CFO; previously CFO at Chinook Therapeutics and Aimmune Therapeutics.
- Base salary of $485,000 and annual bonus target of 40% of base salary.
- Granted option for 110,000 shares and RSU for 55,000 shares, both with four-year vesting.
- Severance: 9-month salary and 12-month equity acceleration outside CIC; 18-month salary +150% bonus + full acceleration within CIC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759425/000119312523232481/0001193125-23-232481-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759425/000119312523232481/d523866d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-232481

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer